LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced the pricing of an underwritten
registered public offering of 1,000,000 shares of its common stock at
$190.00 per share. The Company has granted the underwriters for the
offering a 30-day option to purchase up to 150,000 additional shares of
its common stock at the public offering price, less the underwriting
discount. The offering is expected to close on or about January 27,
2015, subject to customary closing conditions.
BofA Merrill Lynch and J.P. Morgan are acting as lead book-running
managers and Citigroup is acting as joint book-running manager for the
offering. Leerink Partners LLC and Cowen and Company, LLC are acting as
co-managers for the offering.
The offering is being made pursuant to an automatically effective shelf
registration statement filed with the Securities and Exchange Commission
on January 20, 2015. A preliminary prospectus supplement describing the
terms of the offering has been filed with the SEC and is available on
the SEC’s web site at www.sec.gov.
A final prospectus supplement will be filed with the Securities and
Exchange Commission and will form a part of the effective registration
statement. Copies of the final prospectus supplement and the
accompanying prospectus relating to the offering may be obtained, when
available, by contacting BofA Merrill Lynch, 222 Broadway, New York, NY
10038, Attn: Prospectus Department, email: dg.prospectus_requests@baml.com;
J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866)
803-9204; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, phone (800) 831-9146.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
Contact: